Aktieanalys

Xspray Pharma: NDA resubmission anticipated in Q4 - Redeye

{newsItem.title}

Redeye Publicerad: 20 Sep 2024 10:17

Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2024 NDA resubmission for Dasynoc. The updated timeline aligns with our estimates, resulting in no changes to our forecasts or valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1040044/xspray-pharma-nda-resubmission-anticipated-in-q4?utm_source=finwire&utm_medium=RSS

Nyheter om Xspray Pharma

Läses av andra just nu

Om aktien Xspray Pharma

Senaste nytt